Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fengming Tang

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
ESC Heart Failure|February 11, 2021
Type 2 diabetes and heart failure: insights from the global DISCOVER studySuzanne V Arnold, Kamlesh Khunti, Fabrice Bonnet, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Circulation|September 17, 2019
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF TrialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
Nature Medicine|October 29, 2021
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E Nassif, Sheryl L Windsor, Barry A Borlaug, et al.
The Lancet. Diabetes & Endocrinology|July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialMikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
ESC Heart Failure|February 11, 2021
Type 2 diabetes and heart failure: insights from the global DISCOVER studySuzanne V Arnold, Kamlesh Khunti, Fabrice Bonnet, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Circulation|September 17, 2019
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF TrialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
Nature Medicine|October 29, 2021
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E Nassif, Sheryl L Windsor, Barry A Borlaug, et al.
The Lancet. Diabetes & Endocrinology|July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialMikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
Pageof 12